tiprankstipranks
BioLineRx Trials New Sickle Cell Gene Therapy
Company Announcements

BioLineRx Trials New Sickle Cell Gene Therapy

Bioline RX Ltd Sponsored ADR (BLRX) has released an update.

Pick the best stocks and maximize your portfolio:

BioLineRx Ltd. has partnered with St. Jude Children’s Research Hospital to launch a Phase 1 trial evaluating motixafortide for stem cell mobilization in sickle cell disease gene therapy. The trial aims to overcome the limitations of current stem cell collection methods, potentially improving treatment outcomes. Enrollment is set to begin soon, with initial trial data expected in the second half of 2024.

For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBioLineRx Reports Strategic Moves in Q3 2024
TheFlyBioLineRx price target lowered to $9 from $21 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskBioLineRx Secures Key Deals to Boost Shareholder Value
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App